Protalix BioTherapeutics, Inc. Common Stock (PLX) — Analysis Summary
Protalix BioTherapeutics, Inc. Common Stock (PLX) has a market cap of $170.01M with year-over-year revenue growth of -1.2%. Net margin stands at -12.5%. The stock trades at a P/E ratio of 11.1.
Key Takeaways
- Revenue changed -1.2% year-over-year
- Net margin of -12.5%
- P/E ratio of 11.1
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, PLX posted revenue growth of -1.2% and trades at a P/E of 11.1.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.